Strona główna
  • Zamawiaj do paczkomatu
  • Płać wygodnie
  • PZWL - dla zawodowców
  • Obniżka
Complete Accounts of Integrated Drug Discovery and Development

Complete Accounts of Integrated Drug Discovery and Development

Recent Examples from the Pharmaceutical Industry, Volume 3

9780841298644
897,00 zł
807,30 zł Zniżka 89,70 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 807,30 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD lub Pocztę Polską. Kliknij po więcej szczegółów

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni. Kliknij po więcej szczegółów

Opis
Case studies from the pharmaceutical industryThis book describes the continuum from discovery to development. Readers will learn how recent drugs, including grazoprevir, melflufen, relebactam, and tesirine, were developed. The book highlights emerging concepts, new developments, and challenges during the discovery process. Well-known authors from the pharmaceutical industry provide an inside look to traditionally closed-door procedures. Profssional chemists and students alike will find these accounts extremely valuable.
Szczegóły produktu
OUP USA
92120
9780841298644
9780841298644

Opis

Rok wydania
2022
Numer wydania
1
Oprawa
twarda
Liczba stron
400
Wymiary (mm)
178 x 254
Waga (g)
1082
  • Preface ; Chapter 1:: Discovery and Chemical Development of the Use-Dependent Sodium Channel Blocker Vixotrigine for the Treatment of Pain, David R. Witty, David T. MacPherson, Gerard M. P. Giblin, Michael T. Williams, Robbie Chen, Vinny Couming, John Guzowski, Erwin Irdam, William F. Kiesman, Daw-Iong Albert Kwok, Wenli Liang, Tamera L. Mack, Erin M. OBrien, Suzanne M. Opalka, Daniel Patience, Stefan Sahli, Donald G. Walker, and FrederickOsei-Yeboah; Chapter 2:: The Discovery and Chemical Development of BMS-919373:: A Selective IKur Inhibitor for the Potential Treatment of Atrial Fibrillation, Heather J. Finlay, Scott A. Savage, Jason M. Stevens, Steven R. Wisniewski, and Miao Yu; Chapter 3:: Discovery and Development of Omecamtiv Mecarbil:: A Novel Cardiac Myosin Activator for the Potential Treatment of Systolic Heart Failure, Bradley P. Morgan, Seb Caille, and Shawn D. Walker; Chapter 4:: Identification and Development of AMG 986:: A Potent and Efficacious APJ Agonist for the Treatment of Heart Failure, Matthew R. Kaller, Paul Dransfield, Robert P. Farrell, and Ted C. Judd; Chapter 5:: Melflufen:: A Journey from Discovery to Multi-Kilogram Production, Fredrik Lehmann and Johan Wennerberg; Chapter 6:: Discovery and Chemical Development of S 44563, a Dual Bcl-2/Bcl-xL Inhibitor, Christophe Hardouin and Jerome-Benoit Starck; Chapter 7:: Discovery and Chemical Development of Tesirine:: An Antitumor Pyrrolobenzodiazepine Antibody-Drug Conjugate Drug-Linker, Arnaud C. Tiberghien and Jeremy S. Parker; Chapter 8:: Discovery and Chemical Development of Relebactam:: A Potent Beta-Lactamase Inhibitor in Combination with PrimaxinR for the Treatment of Serious and Antibiotic-Resistant Bacterial Infections, Feng Xu, Benjamin D. Sherry, and Timothy A. Blizzard; Chapter 9:: Discovery and Chemical Development of Grazoprevir:: An HCV NS3/4a Protease Inhibitor for the Treatment of the Hepatitis C Virus Infection, Feng Xu and John A. McCauley; Chapter 10:: Discovery and Process Development of BIIB068:: A Reversible Brutons Tyrosine Kinase (BTK) Inhibitor for the Treatment of Autoimmune Diseases, Bin Ma, Chaomin Li, Brian T. Hopkins, Lloyd Franklin, Robbie Chen, Tamera Mack, Daniel Patience, William F. Kiesman, and Erin M. OBrien; Chapter 11:: Discovery and Commercial Development of Cholesteryl Transfer Protein Inhibitor Evacetrapib, Nathan B. Mantlo and Scott A. Frank; Editors Biographies; Author Index; Subject Index ;
Komentarze (0)

  • Często kupowane razem

    Brak dostępnych produktów